Order results by:
Issue | Title | |
Vol 9, No 2 (2016) | BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION | Abstract similar documents |
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak | ||
"... Objectives. To assess the incremental budget impact (BI) of using of utilizing perampanel to treat ..." | ||
Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
"... . Budget impact analysis for the partial replacement of omalizumab with mepolizumab and/or reslizumab has ..." | ||
Vol 12, No 1 (2019) | Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan | Abstract similar documents |
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova | ||
"... optimization in the Republic of Tatarstan. Materials and methods. A budget impact model was created to compare ..." | ||
Vol 13, No 4 (2020) | Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy | Abstract similar documents |
I. N. Dyakov, S. R. Varfolomeеva | ||
"... -effectiveness analysis) with a sensitivity analysis; and a "budget impact" analysis with a sensitivity analysis ..." | ||
Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
S. К. Zyryanov, I. N. Dyakov | ||
"... ,165.00 rubles (–0.4%). The budget impact analysis showed that an increase in the proportion of patients ..." | ||
Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
"... parameters, budget impact analysis were carried out. Results. The total medical costs for CP/EP + ATZ course ..." | ||
Vol 15, No 2 (2022) | Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation | Abstract similar documents |
S. К. Zyryanov, I. N. Dyakov | ||
Vol 17, No 4 (2024) | Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment | Abstract similar documents |
S. К. Zyryanov, I. N. Dyakov | ||
"... and budget impact analysis, with consideration to the efficacy of the compared therapeutic regimens. Data ..." | ||
Vol 15, No 1 (2022) | Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies | Abstract similar documents |
K. A. Perova, D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, N. Z. Musina | ||
"... of the budget impact analysis included the costs required for the ovarian stimulation of patients distributed ..." | ||
Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
"... (treated separately), ART program cycle, relief of complications. As part of the budget impact analysis ..." | ||
Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract similar documents |
S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
"... and budget impact analyses were performed. Results. The drug costs for T+O were the lowest among all ..." | ||
Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract similar documents |
S. K. Zyryanov, I. N. Dyakov | ||
"... and third lines of NSCLC therapy. The budget impact analysis demonstrated that if all patients in the target ..." | ||
1 - 12 of 12 Items |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)